Press Releases

IGC-Pharma-Calma-Phase2-Alzheimer’s-Market
IGC Pharma’s Puerto Rico CALMA Trial Site Offers Strategic Opportunity in High-Prevalence Alzheimer’s Market
Read More →
IGC-Pharma-Alzheimers-Melatonin-Toxicity-Safety
IGC Pharma Presents Genetic Toxicology Safety Data on API in IGC-AD1, at the 2025 Genetic Toxicology Association Meeting
Read More →
IGC-Pharma-Alzheimers-Innovation-AI-Advisory (2)
IGC Pharma Welcomes Strategic Investment from Advisors
Read More →
IGC-Pharma-Alzheimers-Innovation-AI-Advisory
IGC Pharma Welcomes Industry Leaders to Advisory Board, Supporting Alzheimer’s Innovation and AI-Driven Programs  
Read More →
IGC-Pharma-Alzheimers-Butler-Hospital-Aging
IGC Pharma Expands CALMA Alzheimer’s Phase 2 Trial with Prestigious Research Site at Butler Hospital’s Memory and Aging Program  
Read More →
IGC-Pharma-Alzheimers-Miami-Jewish-Trial
IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Miami Jewish Health  
Read More →
IGC-Pharma-Alzheimers-Reduction-Sleep-Disturbances
IGC Pharma’s Phase 2 Clinical Trial Interim Data Demonstrates Significant Reduction in Sleep Disturbances  
Read More →
IGC-Pharma-Alzheimers-Hamilton-Health-Trial
IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Canadian Hamilton Health Sciences    
Read More →
IGC-Pharma-Alzheimers-BayCare-Health-Trial-Florida
IGC Pharma Expands CALMA Trial with Addition of BayCare Health System in Florida
Read More →
IGC-Pharma-Alzheimers-Equity-Analyst-Coverage-AGP (1)
IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the Reports Q3 results. We believe more positive clinical data in 2025 to be strong catalysts for stock. Raising P/T to $4.25” 
Read More →
IGC-Pharma-Alzheimers-Equity-Analyst-Coverage-AGP
IGC Pharma Announces Equity Analyst Update by Alliance Global Partners (AGP) about the “Progressing Alzheimer-targeting efforts with notable Phase 2 CALMA interim results”
Read More →
IGC-Pharma-Alzheimers-AI-Dementia-Diagnostic
IGC Pharma Expands AI Platform with Advanced Diagnostic Model for Alzheimer’s and Dementia Detection  
Read More →
IGC-Pharma-Alzheimers-Lions-Mane-Turkey-tail-Longevity-Renew
IGC Pharma Expands Holiby™ Product Line with –Longevity’ and –Renew’ – Targeting the Multi-Billion-Dollar Anti-Aging Market  
Read More →
IGC-Pharma-Alzheimers-Reports-Fiscal Results
IGC Pharma Reports Third Quarter Fiscal 2025 Results  
Read More →
IGC-Pharma-Alzheimers-Ashwagandha-Elderberry-Immunity-Energy
IGC Pharma Expands into $75 Billion Wellness Market with the Launch of Holiby™    
Read More →
IGC-Pharma-Alzheimers-Nia-Prepare-Challenge
IGC Pharma Named Top 15 Finalist in NIA PREPARE Challenge for AI-Driven Early Detection of Alzheimer’s Disease  
Read More →